154 related articles for article (PubMed ID: 19944081)
1. Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease.
Rustay NR; Cronin EA; Curzon P; Markosyan S; Bitner RS; Ellis TA; Waring JF; Decker MW; Rueter LE; Browman KE
Brain Res; 2010 Jan; 1311():136-47. PubMed ID: 19944081
[TBL] [Abstract][Full Text] [Related]
2. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL
J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease.
Hashimoto T; Ogino K; Shin RW; Kitamoto T; Kikuchi T; Shimizu N
Neurosci Lett; 2010 Jan; 469(2):273-7. PubMed ID: 20025930
[TBL] [Abstract][Full Text] [Related]
4. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
[TBL] [Abstract][Full Text] [Related]
5. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice.
Knobloch M; Konietzko U; Krebs DC; Nitsch RM
Neurobiol Aging; 2007 Sep; 28(9):1297-306. PubMed ID: 16876915
[TBL] [Abstract][Full Text] [Related]
6. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
[TBL] [Abstract][Full Text] [Related]
7. Behavioural phenotype of APPC100.V717F transgenic mice over-expressing a mutant Abeta-bearing fragment is associated with reduced NMDA receptor density.
Boon WC; van den Buuse M; Wegener N; Martin S; Chua HK; Bush AI; Masters CL; Adlard PA; Li QX
Behav Brain Res; 2010 May; 209(1):27-35. PubMed ID: 20085783
[TBL] [Abstract][Full Text] [Related]
8. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
Lewis J; Dickson DW; Lin WL; Chisholm L; Corral A; Jones G; Yen SH; Sahara N; Skipper L; Yager D; Eckman C; Hardy J; Hutton M; McGowan E
Science; 2001 Aug; 293(5534):1487-91. PubMed ID: 11520987
[TBL] [Abstract][Full Text] [Related]
9. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice.
Bernardo A; Harrison FE; McCord M; Zhao J; Bruchey A; Davies SS; Jackson Roberts L; Mathews PM; Matsuoka Y; Ariga T; Yu RK; Thompson R; McDonald MP
Neurobiol Aging; 2009 Nov; 30(11):1777-91. PubMed ID: 18258340
[TBL] [Abstract][Full Text] [Related]
10. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice.
Hartmann J; Erb C; Ebert U; Baumann KH; Popp A; König G; Klein J
Neuroscience; 2004; 125(4):1009-17. PubMed ID: 15120860
[TBL] [Abstract][Full Text] [Related]
11. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease.
Filali M; Lalonde R
Brain Res; 2009 Oct; 1292():93-9. PubMed ID: 19643098
[TBL] [Abstract][Full Text] [Related]
12. Reduced brain volumes in mice expressing APP-Austrian mutation but not in mice expressing APP-Swedish-Austrian mutations.
Van Broeck B; Vanhoutte G; Cuijt I; Pereson S; Joris G; Timmermans JP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurosci Lett; 2008 Dec; 447(2-3):143-7. PubMed ID: 18840503
[TBL] [Abstract][Full Text] [Related]
13. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
[TBL] [Abstract][Full Text] [Related]
14. Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice.
Kawasumi M; Chiba T; Yamada M; Miyamae-Kaneko M; Matsuoka M; Nakahara J; Tomita T; Iwatsubo T; Kato S; Aiso S; Nishimoto I; Kouyama K
Eur J Neurosci; 2004 May; 19(10):2826-38. PubMed ID: 15147316
[TBL] [Abstract][Full Text] [Related]
15. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
16. The occurrence of a deficit in contextual fear extinction in adult amyloid-over-expressing TASTPM mice is independent of the strength of conditioning but can be prevented by mild novel cage stress.
Rattray I; Scullion GA; Soulby A; Kendall DA; Pardon MC
Behav Brain Res; 2009 Jun; 200(1):83-90. PubMed ID: 19162086
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral Abeta deposition.
Blanchard J; Decorte L; Noguès X; Micheau J
Behav Brain Res; 2009 Jul; 201(1):147-57. PubMed ID: 19428628
[TBL] [Abstract][Full Text] [Related]
18. Effects of the genetic background on cognitive performances of TG2576 mice.
Lassalle JM; Halley H; Daumas S; Verret L; Francés B
Behav Brain Res; 2008 Aug; 191(1):104-10. PubMed ID: 18433892
[TBL] [Abstract][Full Text] [Related]
19. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain.
Arendash GW; Lewis J; Leighty RE; McGowan E; Cracchiolo JR; Hutton M; Garcia MF
Brain Res; 2004 Jun; 1012(1-2):29-41. PubMed ID: 15158158
[TBL] [Abstract][Full Text] [Related]
20. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease.
Watanabe T; Yamagata N; Takasaki K; Sano K; Hayakawa K; Katsurabayashi S; Egashira N; Mishima K; Iwasaki K; Fujiwara M
Brain Res; 2009 Jan; 1249():222-8. PubMed ID: 18996097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
